<i>TARDBP</i> mutations in motoneuron disease with frontotemporal lobar degenerationLina Benajiba, Alexis Brice, Catherine Thomas-Antérion et al.|Annals of Neurology|2009Cited by 302
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, Massimo Locati, P. Nigel Leigh et al.|The Lancet|2025Cited by 33